keyword
MENU ▼
Read by QxMD icon Read
search

vonoprazan

keyword
https://www.readbyqxmd.com/read/28216974/comparative-study-vonoprazan-and-proton-pump-inhibitors-in-helicobacter-pylori-eradication-therapy
#1
Kouichi Sakurai, Hiroko Suda, Yumi Ido, Takayuki Takeichi, Ayako Okuda, Kiwamu Hasuda, Masahiro Hattori
AIM: To compare the effectiveness and safety of vonoprazan-based therapy with proton pump inhibitor (PPI)-based therapies to treat Helicobacter pylori (H. pylori). METHODS: We retrospectively analysed data from first-line (vonoprazan or PPI with 200 mg clarithromycin and 750 mg amoxicillin twice daily for 7 d) (n = 1353) and second-line (vonoprazan or PPI with 250 mg metronidazole and 750 mg amoxicillin twice daily for 7 d) (n = 261) eradication treatments for H...
January 28, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28198590/effect-of-therapeutic-and-supratherapeutic-doses-of-vonoprazan-on-the-qt-qtc-interval-in-a-phase-i-randomized-study-in-healthy-subjects
#2
B Astruc, H Jenkins, R Jenkins
This phase I, randomized, 4-period, 4-sequence, double-blind, active- and placebo-controlled, crossover study assessed the effects of vonoprazan on the QT/QTc interval in healthy subjects. Subjects received single oral doses of vonoprazan 40 mg, vonoprazan 120 mg, moxifloxacin 400 mg (positive control/open label), and placebo. The primary end point was time-matched, placebo-corrected, baseline-adjusted mean Fridericia-corrected QT interval (ddQTcF). Of 64 subjects (mean age, 37.8 years; 50% male), 63 received all four regimens...
February 15, 2017: Clinical and Translational Science
https://www.readbyqxmd.com/read/28098408/vonoprazan-improves-the-efficacy-of-helicobacter-pylori-eradication-therapy-with-a-regimen-consisting-of-clarithromycin-and-metronidazole-in-patients-allergic-to-penicillin
#3
Shoko Ono, Mototsugu Kato, Soichi Nakagawa, Katsuhiro Mabe, Naoya Sakamoto
BACKGROUND: Although all Helicobacter pylori (H. pylori)-positive patients should receive eradication therapy, the therapy is a challenge for patients allergic to penicillin. There have been a few reports on the efficacy of eradication therapy for such patients. OBJECTIVE: To analyze the efficacy of vonoprazan or proton pump inhibitor (PPI)-based 7-day triple therapy in patients allergic to penicillin. MATERIALS AND METHODS: A total of 88 consecutive patients allergic to penicillin who received H...
January 18, 2017: Helicobacter
https://www.readbyqxmd.com/read/28030862/a-comparative-study-of-a-new-class-of-gastric-acid-suppressant-agent-named-vonoparazan-versus-esomeprazole-for-the-eradication-of-helicobacter-pylori
#4
Masahiro Tsujimae, Hiroshi Yamashita, Hiroki Hashimura, Chise Kano, Keiko Shimoyama, Atsushi Kanamori, Kei Matsumoto, Akio Koizumi, Kenji Momose, Takaaki Eguchi, Takumi Fukuchi, Mikio Fujita, Akihiko Okada
BACKGROUND: Helicobacter pylori eradication rates have decreased worldwide. Gastric acid inhibition during treatment is important to eradicate these bacteria successfully. A new potassium-competitive acid blocker, vonoprazan (VPZ), has been shown to achieve high eradication rates in a previous randomized controlled trial. OBJECTIVE: To determine the efficacy of VPZ for H. pylori eradication. METHODS: A total of 874 patients were enrolled; 431 received esomeprazole (EPZ) and 443 received VPZ...
2016: Digestion
https://www.readbyqxmd.com/read/27988924/successful-eradication-therapy-for-helicobacter-pylori-positive-atrophic-gastritis-at-the-sixth-attempt-a-case-report
#5
Ryuzo Deguchi, Koichi Shiraishi, Yoshitaka Arase, Makiko Dekiden, Hideo Shimada, Hiroshi Miyakita, Takashi Ogimi, Kazunori Myojin, Tetsuya Mine
A 74-year-old woman undergoing outpatient follow-up for reflux esophagitis and atrophic gastritis tested positive for Helicobacter pylori and underwent primary eradication therapy with lansoprazole (LPZ) 30 mg, amoxicillin (AMPC) 750 mg, and clarithromycin (CAM) 200 mg twice daily for 1 week in August 2012. A urea breath test (UBT) after this treatment revealed that eradication had failed. Secondary eradication therapy was carried out with esomeprazole (EPZ) 20 mg, AMPC 750 mg, and metronidazole (MNZ) 250 mg twice daily for 1 week, but this also failed...
December 20, 2016: Tokai Journal of Experimental and Clinical Medicine
https://www.readbyqxmd.com/read/27928738/effect-of-multiple-oral-doses-of-the-potent-cyp3a4-inhibitor-clarithromycin-on-the-pharmacokinetics-of-a-single-oral-dose-of-vonoprazan-a-phase-i-open-label-sequential-design-study
#6
Helen Jenkins, Richard Jenkins, Alain Patat
BACKGROUND AND OBJECTIVES: This phase I, open-label, sequential design study assessed the effect of multiple oral doses of the potent cytochrome P450 (CYP) 3A4 inhibitor clarithromycin on the pharmacokinetics of a single oral dose of vonoprazan. METHODS: During the 10-day treatment period, 16 healthy male subjects received vonoprazan 40 mg on days 1 and 8, and clarithromycin 1000 mg on days 3-9, with the pharmacokinetics of both examined. Primary endpoints included the maximum observed plasma concentration (C max) and area under the plasma concentration-time curve (AUC) of vonoprazan and its major metabolites (M-I, M-II, M-III, and M-IV-Sul)...
March 2017: Clinical Drug Investigation
https://www.readbyqxmd.com/read/27909552/vonoprazan-20-mg-vs-lansoprazole-30-mg-for-endoscopic-submucosal-dissection-induced-gastric-ulcers
#7
Kazuya Takahashi, Yuichi Sato, Junji Kohisa, Jun Watanabe, Hiroki Sato, Kenichi Mizuno, Satoru Hashimoto, Shuji Terai
AIM: To compare the healing effects of vonoprazan and lansoprazole on gastric ulcers induced by endoscopic submucosal dissection (ESD). METHODS: Data were obtained from a total of 26 patients. Fourteen patients were randomized to the vonoprazan group and 12 were randomized to the lansoprazole group. Patients were administered either 20 mg vonoprazan or 30 mg lansoprazole per day after ESD. Endoscopic images just after ESD, on day 8, and on day 28 were used for the evaluation of the shrinking rate of ESD ulcers...
November 16, 2016: World Journal of Gastrointestinal Endoscopy
https://www.readbyqxmd.com/read/27891632/randomised-clinical-trial-efficacy-and-safety-of-vonoprazan-vs-lansoprazole-in-patients-with-gastric-or-duodenal-ulcers-results-from-two-phase-3-non-inferiority-randomised-controlled-trials
#8
H Miwa, N Uedo, J Watari, Y Mori, Y Sakurai, Y Takanami, A Nishimura, T Tatsumi, N Sakaki
BACKGROUND: Vonoprazan is a new potassium-competitive acid blocker for treatment of acid-related diseases. AIM: To conduct two randomised-controlled trials, to evaluate the non-inferiority of vonoprazan vs. lansoprazole, a proton pump inhibitor, for treatment of gastric ulcer (GU) or duodenal ulcer (DU). METHODS: Patients aged ≥20 years with ≥1 endoscopically-confirmed GU or DU (≥5 mm white coating) were randomised 1:1 using double-dummy blinding to receive lansoprazole (30 mg) or vonoprazan (20 mg) for 8 (GU study) or 6 (DU study) weeks...
January 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27888863/helicobacter-pylori-related-diseases
#9
Javier P Gisbert
This article describes the main conclusions drawn from the presentations on Helicobacter pylori infection in Digestive Diseases Week, 2016. Despite the undeniable widespread reduction in the prevalence of this infection, infection rates continue to be high in developing countries. The prevalence of clarithromycin, metronidazole and quinolone resistance is markedly high in most countries and continues to rise. The management of H. pylori infection in patients with peptic ulcers still leaves much to be desired...
September 2016: Gastroenterología y Hepatología
https://www.readbyqxmd.com/read/27867688/usefulness-of-vonoprazan-a-potassium-ion-competitive-acid-blocker-for-primary-eradication-of-helicobacter-pylori
#10
Shinya Yamada, Takumi Kawakami, Yoshikazu Nakatsugawa, Takahiro Suzuki, Hideki Fujii, Naoya Tomatsuri, Hideki Nakamura, Hideki Sato, Yusuke Okuyama, Hiroyuki Kimura, Norimasa Yoshida
AIM: To investigate usefulness of triple therapy with vonoprazan, a potassium ion-competitive acid blocker and antibiotics, for Helicobacter pylori (H. pylori) eradication. METHODS: The H. pylori eradication rate was examined in 2507 patients (2055 undergoing primary eradication and 452 undergoing secondary eradication, excluding patients with subtotal gastrectomy) at the Japanese Red Cross Kyoto Daiichi Hospital from March 2013 to September 2015. For patients treated from March 2013 to February 2015, a proton pump inhibitor (PPI) was used to reduce acid secretion, while vonoprazan was used after March 2015...
November 6, 2016: World Journal of Gastrointestinal Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/27859641/effects-of-vonoprazan-on-intractable-non-steroidal-anti-inflammatory-drug-induced-ulcers-that-cannot-be-controlled-with-conventional-proton-pump-inhibitors
#11
LETTER
Kazuhiro Mizukami, Kazunari Murakami
No abstract text is available yet for this article.
November 17, 2016: Digestive Endoscopy: Official Journal of the Japan Gastroenterological Endoscopy Society
https://www.readbyqxmd.com/read/27806639/analysis-of-the-cost-effectiveness-of-using-vonoprazan-amoxicillin-clarithromycin-triple-therapy-for-first-line-helicobacter-pylori-eradication
#12
Yusaku Kajihara, Tadashi Shimoyama, Ichiro Mizuki
BACKGROUND: Vonoprazan (VPZ)-based triple therapy has been reported to have greater efficacy than a proton pump inhibitor (PPI)-based triple therapy for Helicobacter pylori (H. pylori) eradication. However, because VPZ is more expensive than PPIs such as rabeprazole (RPZ), economic evaluation is essential. METHODS: We performed a retrospective study on 209 patients who underwent first-line eradication of H. pylori infection in Fuyoukai Murakami Hospital from 1 March 2015 to 31 March 2016...
February 2017: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/27803739/vonoprazan-based-therapy-for-helicobacter-pylori-eradication-experience-and-clinical-evidence
#13
REVIEW
Yuko Akazawa, Daisuke Fukuda, Yutaka Fukuda
Stable suppression of gastric acid secretion is a crucial factor in Helicobacter pylori eradication. Vonoprazan is a potassium-competitive acid blocker recently approved for use in Japan. As vonoprazan has a long duration of action and causes rapid and strong inhibition of gastric acid secretion, it has gained clinical attention for treating erosive oesophagitis, peptic ulcers, and H. pylori infection. In this review, we discuss the recent knowledge regarding the safety and efficacy of vonoprazan, focusing on its use in H...
November 2016: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/27689190/a-novel-potassium-competitive-acid-blocker-improves-the-efficacy-of-clarithromycin-containing-7-day-triple-therapy-against-helicobacter-pylori
#14
Hisatsugu Noda, Seiji Noguchi, Takashi Yoshimine, Shigeki Goji, Kazunori Adachi, Yasuhiro Tamura, Shinya Izawa, Masahide Ebi, Sayuri Yamamoto, Naotaka Ogasawara, Yasushi Funaki, Makoto Sasaki, Kunio Kasugai
BACKGROUND AND AIMS: In Japan, 7-day triple therapy for Helicobacter pylori including clarithromycin (CAM) was approved in 2000. However, antibiotic resistance subsequently reduced this rate to an unacceptable level (70%). Vonoprazan, an orally bioavailable potassium-competitive acid blocker (P-CAB), was approved in Japan in 2014. This could improve eradication rates by increasing the intragastric pH, thus increasing bacterial antibiotic susceptibility. This study compared the efficacy of 7-day triple therapies that included CAM and vonoprazan or proton pump inhibitor (PPI)...
September 2016: Journal of Gastrointestinal and Liver Diseases: JGLD
https://www.readbyqxmd.com/read/27659671/helicobacter-pylori-eradication-with-proton-pump-inhibitors-or-potassium-competitive-acid-blockers-the-effect-of-clarithromycin-resistance
#15
Hiroshi Matsumoto, Akiko Shiotani, Ryo Katsumata, Minoru Fujita, Rui Nakato, Takahisa Murao, Manabu Ishii, Tomoari Kamada, Ken Haruma, David Y Graham
BACKGROUND: Vonoprazan is a novel potassium-competitive acid blocker (P-CAB) recently approved for Helicobacter pylori eradication therapy in Japan. AIMS: To compare PPI- and P-CAP-containing triple therapy and vonoprazan-based triple therapy. METHODS: Two hundred ninety-five initial subjects received a PPI-containing triple therapy; the next 125 subjects received vonoprazan-containing triple therapy. Two sequential groups received 7-day eradication regimens consisting of amoxicillin 750 mg, clarithromycin 200 mg both twice a day with standard dose PPI or vonoprazan (20 mg) each twice daily...
November 2016: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/27582888/safety-and-efficacy-of-vonoprazan-based-triple-therapy-against-helicobacter-pylori-infection-a-single-center-experience-with-1118-patients
#16
Daisuke Fukuda, Yuko Akazawa, Fuminao Takeshima, Kazuhiko Nakao, Yutaka Fukuda
No abstract text is available yet for this article.
September 2016: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/27581248/pharmacokinetic-drug-drug-interactions-between-vonoprazan-and-low-dose-aspirin-or-nonsteroidal-anti-inflammatory-drugs-a-phase-2-open-label-study-in-healthy-japanese-men
#17
Yuuichi Sakurai, Madoka Shiino, Sayako Horii, Hiroyuki Okamoto, Koki Nakamura, Akira Nishimura, Yukikuni Sakata
BACKGROUND: Gastroprotective agents are recommended for patients receiving low-dose aspirin (LDA) or nonsteroidal anti-inflammatory drugs (NSAIDs). Vonoprazan is a potassium-competitive acid blocker recently approved for the prevention of peptic ulcer recurrence in patients receiving LDA or NSAIDs. METHODS: This phase 2, open-label, single-center study in healthy Japanese males evaluated drug-drug interactions between vonoprazan 40 mg and LDA (100 mg) or NSAIDs [loxoprofen sodium (60 mg), diclofenac sodium (25 mg), or meloxicam (10 mg)] and vice versa...
January 2017: Clinical Drug Investigation
https://www.readbyqxmd.com/read/27534444/vonoprazan-versus-conventional-proton-pump-inhibitor-based-triple-therapy-as-first-line-treatment-against-helicobacter-pylori-a-multicenter-retrospective-study-in-clinical-practice
#18
Satoki Shichijo, Yoshihiro Hirata, Ryota Niikura, Yoku Hayakawa, Atsuo Yamada, Satoshi Mochizuki, Keigo Matsuo, Yoshihiro Isomura, Motoko Seto, Nobumi Suzuki, Hirobumi Suzuki, Shinzo Yamamoto, Takafumi Sugimoto, Tomoya Omae, Makoto Okamoto, Hirotsugu Watabe, Goichi Togo, Noriyuki Takano, Keisuke Fukui, Yuri Ito, Kazuhiko Koike
OBJECTIVE: Vonoprazan is a potassium-competitive acid blocker, a new type of acid-suppressing drug, and has recently become available for peptic ulcers, gastroesophageal reflux disease, and Helicobacter pylori (H. pylori) eradication. Its efficacy for H. pylori eradication has been reported. However, the evidence for its efficacy and feasibility remains limited. We aimed to compare the feasibility, effectiveness and safety of vonoprazan-based triple therapy with conventional proton pump inhibitor (PPI)-based triple therapy in multicenter clinical practice...
October 2016: Journal of Digestive Diseases
https://www.readbyqxmd.com/read/27514776/potassium-competitive-acid-blockers-advanced-therapeutic-option-for-acid-related-diseases
#19
Nobuhiro Inatomi, Jun Matsukawa, Yuuichi Sakurai, Kazuyoshi Otake
Acid-related diseases (ARDs), such as peptic ulcers and gastroesophageal reflux disease, represent a major health-care concern. Some major milestones in our understanding of gastric acid secretion and ARD treatment reached during the last 50years include 1) discovery of histamine H2-receptors and development of H2-receptor antagonists, 2) identification of H(+),K(+)-ATPase as the parietal cell proton pump and development of proton pump inhibitors (PPIs), and 3) identification of Helicobacter pylori (H. pylori) as the major cause of peptic ulcers and development of effective eradication regimens...
December 2016: Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27492962/vonoprazan-is-superior-to-proton-pump-inhibitors-in-healing-artificial-ulcers-of-the-stomach-post-endoscopic-submucosal-dissection-a-propensity-score-matching-analysis
#20
Daisuke Maruoka, Makoto Arai, Shingo Kasamatsu, Hideaki Ishigami, Takashi Taida, Kenichiro Okimoto, Keiko Saito, Tomoaki Matsumura, Tomoo Nakagawa, Tatsuro Katsuno, Osamu Yokosuka
BACKGROUND AND AIM: Proton pump inhibitors (PPI) are effective at healing artificial ulcers after endoscopic submucosal dissection (ESD) for gastric neoplasms; however, the efficacy of vonoprazan is not completely understood. The aim of the present study was to determine the healing effect of vonoprazan on artificial ulcers post-gastric ESD relative to PPI. METHODS: Thirty-five patients who underwent gastric ESD between April and November 2015 were treated with vonoprazan 20 mg/day for 4 weeks and subsequently underwent endoscopy for evaluation of ulcer size (V group)...
August 4, 2016: Digestive Endoscopy: Official Journal of the Japan Gastroenterological Endoscopy Society
keyword
keyword
99659
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"